APO Research
Talk to an analyst

APO RESEARCH · REPORT

Liraglutide

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.

Selected research

Market Outlook & Growth Opportunities

Global Liraglutide Market Outlook and Growth Opportunities 2026

21 December 2025196 pages

Choose your research edition.

Industry ResearchLiraglutide Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Liraglutide Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Liraglutide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liraglutide Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Liraglutide Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.

The global Liraglutide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Liraglutide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Europe market for Liraglutide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Liraglutide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Liraglutide market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Liraglutide market include HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, Wuxi Asiapeptide and AmbioPharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Liraglutide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Liraglutide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liraglutide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liraglutide market size, projected growth trends, production technologies, key applications, and end-use industries.

Liraglutide Segment by Company

HEC Pharm

Bachem

Bharat Pharmaceuticals

Kingpep Biotechnology

Shenzhen JYMed Technology

Wuxi Asiapeptide

AmbioPharm

Liraglutide Segment by Type

Pills

Liquid

Liraglutide Segment by Application

Hospital

Drug Store

Liraglutide Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Liraglutide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Liraglutide market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Liraglutide significant trends, drivers, influence factors in global and regions.

6. To analyze Liraglutide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liraglutide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liraglutide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liraglutide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Liraglutide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liraglutide industry.

Chapter 3: Detailed analysis of Liraglutide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Liraglutide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Liraglutide in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Liraglutide Industry Trends Table 2. Liraglutide Industry Drivers Table 3. Liraglutide Industry Opportunities and Challenges Table 4. Liraglutide Industry Restraints Table 5. Global Liraglutide Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Liraglutide Revenue Share by Company (2021-2026) Table 7. Global Liraglutide Sales Volume by Company (K MT) & (2021-2026) Table 8. Global Liraglutide Sales Volume Share by Company (2021-2026) Table 9. Global Liraglutide Average Price (USD/MT) of Company (2021-2026) Table 10. Global Liraglutide Company Ranking, (2024-2026) & (USD Million) Table 11. Global Liraglutide Key Company Manufacturing Base & Headquarters Table 12. Global Liraglutide Company, Product Type & Application Table 13. Global Liraglutide Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Liraglutide by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pills Table 18. Significant Companies of Liquid Table 19. Global Liraglutide Sales Volume by Type 2021 VS 2025 VS 2032 (K MT) Table 20. Global Liraglutide Sales Volume by Type (2021-2026) & (K MT) Table 21. Global Liraglutide Sales Volume by Type (2027-2032) & (K MT) Table 22. Global Liraglutide Sales Volume Share by Type (2021-2026) Table 23. Global Liraglutide Sales Volume Share by Type (2027-2032) Table 24. Global Liraglutide Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Liraglutide Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Liraglutide Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Liraglutide Sales Value Share by Type (2021-2026) Table 28. Global Liraglutide Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Drug Store Table 31. Global Liraglutide Sales Volume by Application 2021 VS 2025 VS 2032 (K MT) Table 32. Global Liraglutide Sales Volume by Application (2021-2026) & (K MT) Table 33. Global Liraglutide Sales Volume by Application (2027-2032) & (K MT) Table 34. Global Liraglutide Sales Volume Share by Application (2021-2026) Table 35. Global Liraglutide Sales Volume Share by Application (2027-2032) Table 36. Global Liraglutide Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Liraglutide Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Liraglutide Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Liraglutide Sales Value Share by Application (2021-2026) Table 40. Global Liraglutide Sales Value Share by Application (2027-2032) Table 41. Global Liraglutide Sales by Region: 2021 VS 2025 VS 2032 (K MT) Table 42. Global Liraglutide Sales by Region (2021-2026) & (K MT) Table 43. Global Liraglutide Sales Market Share by Region (2021-2026) Table 44. Global Liraglutide Sales by Region (2027-2032) & (K MT) Table 45. Global Liraglutide Sales Market Share by Region (2027-2032) Table 46. Global Liraglutide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Liraglutide Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Liraglutide Sales Value Share by Region (2021-2026) Table 49. Global Liraglutide Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Liraglutide Sales Value Share by Region (2027-2032) Table 51. Global Liraglutide Market Average Price (USD/MT) by Region (2021-2026) Table 52. Global Liraglutide Market Average Price (USD/MT) by Region (2027-2032) Table 53. Global Liraglutide Sales by Country: 2021 VS 2025 VS 2032 (K MT) Table 54. Global Liraglutide Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Liraglutide Sales by Country (2021-2026) & (K MT) Table 56. Global Liraglutide Sales Market Share by Country (2021-2026) Table 57. Global Liraglutide Sales by Country (2027-2032) & (K MT) Table 58. Global Liraglutide Sales Market Share by Country (2027-2032) Table 59. Global Liraglutide Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Liraglutide Sales Value Market Share by Country (2021-2026) Table 61. Global Liraglutide Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Liraglutide Sales Value Market Share by Country (2027-2032) Table 63. HEC Pharm Company Information Table 64. HEC Pharm Business Overview Table 65. HEC Pharm Liraglutide Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 66. HEC Pharm Liraglutide Product Portfolio Table 67. HEC Pharm Recent Development Table 68. Bachem Company Information Table 69. Bachem Business Overview Table 70. Bachem Liraglutide Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 71. Bachem Liraglutide Product Portfolio Table 72. Bachem Recent Development Table 73. Bharat Pharmaceuticals Company Information Table 74. Bharat Pharmaceuticals Business Overview Table 75. Bharat Pharmaceuticals Liraglutide Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 76. Bharat Pharmaceuticals Liraglutide Product Portfolio Table 77. Bharat Pharmaceuticals Recent Development Table 78. Kingpep Biotechnology Company Information Table 79. Kingpep Biotechnology Business Overview Table 80. Kingpep Biotechnology Liraglutide Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 81. Kingpep Biotechnology Liraglutide Product Portfolio Table 82. Kingpep Biotechnology Recent Development Table 83. Shenzhen JYMed Technology Company Information Table 84. Shenzhen JYMed Technology Business Overview Table 85. Shenzhen JYMed Technology Liraglutide Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 86. Shenzhen JYMed Technology Liraglutide Product Portfolio Table 87. Shenzhen JYMed Technology Recent Development Table 88. Wuxi Asiapeptide Company Information Table 89. Wuxi Asiapeptide Business Overview Table 90. Wuxi Asiapeptide Liraglutide Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 91. Wuxi Asiapeptide Liraglutide Product Portfolio Table 92. Wuxi Asiapeptide Recent Development Table 93. AmbioPharm Company Information Table 94. AmbioPharm Business Overview Table 95. AmbioPharm Liraglutide Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 96. AmbioPharm Liraglutide Product Portfolio Table 97. AmbioPharm Recent Development Table 98. Key Raw Materials Table 99. Raw Materials Key Suppliers Table 100. Liraglutide Distributors List Table 101. Liraglutide Customers List Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Liraglutide Product Image Figure 2. Global Liraglutide Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liraglutide Sales Value (2021-2032) & (US$ Million) Figure 4. Global Liraglutide Sales (2021-2032) & (K MT) Figure 5. Global Liraglutide Sales Average Price (USD/MT) & (2021-2032) Figure 6. Global Liraglutide Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pills Image Figure 10. Liquid Image Figure 11. Global Liraglutide Sales Volume by Type (2021 VS 2025 VS 2032) & (K MT) Figure 12. Global Liraglutide Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Liraglutide Sales Volume Share by Type (2021-2032) Figure 14. Global Liraglutide Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Liraglutide Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Liraglutide Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Drug Store Image Figure 19. Global Liraglutide Sales Volume by Application (2021 VS 2025 VS 2032) & (K MT) Figure 20. Global Liraglutide Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Liraglutide Sales Volume Share by Application (2021-2032) Figure 22. Global Liraglutide Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Liraglutide Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Liraglutide Sales Value Share by Application (2021-2032) Figure 25. Global Liraglutide Sales by Region: 2021 VS 2025 VS 2032 (K MT) Figure 26. Global Liraglutide Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Liraglutide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Liraglutide Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Liraglutide Sales Value (2021-2032) & (US$ Million) Figure 30. North America Liraglutide Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Liraglutide Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Liraglutide Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Liraglutide Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Liraglutide Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Liraglutide Sales Value (2021-2032) & (US$ Million) Figure 36. South America Liraglutide Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Liraglutide Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Liraglutide Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Liraglutide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Liraglutide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Liraglutide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Liraglutide Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Liraglutide Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Pills
  • Liquid
Applications
  • Hospital
  • Drug Store
Companies covered
  • HEC Pharm
  • Bachem
  • Bharat Pharmaceuticals
  • Kingpep Biotechnology
  • Shenzhen JYMed Technology
  • Wuxi Asiapeptide
  • AmbioPharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Liraglutide Sales Value (2021-2032)
  4. 1.2.2 Global Liraglutide Sales Volume (2021-2032)
  5. 1.2.3 Global Liraglutide Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Liraglutide Market Dynamics
  1. 2.1 Liraglutide Industry Trends
  2. 2.2 Liraglutide Industry Drivers
  3. 2.3 Liraglutide Industry Opportunities and Challenges
  4. 2.4 Liraglutide Industry Restraints
3 Liraglutide Market by Company
  1. 3.1 Global Liraglutide Company Revenue Ranking in 2025
  2. 3.2 Global Liraglutide Revenue by Company (2021-2026)
  3. 3.3 Global Liraglutide Sales Volume by Company (2021-2026)
  4. 3.4 Global Liraglutide Average Price by Company (2021-2026)
  5. 3.5 Global Liraglutide Company Ranking (2024-2026)
  6. 3.6 Global Liraglutide Company Manufacturing Base and Headquarters
  7. 3.7 Global Liraglutide Company Product Type and Application
  8. 3.8 Global Liraglutide Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Liraglutide Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Liraglutide Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Liraglutide Market by Type
  1. 4.1 Liraglutide Type Introduction
  2. 4.1.1 Pills
  3. 4.1.2 Liquid
  4. 4.2 Global Liraglutide Sales Volume by Type
  5. 4.2.1 Global Liraglutide Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Liraglutide Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Liraglutide Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Liraglutide Sales Value by Type
  9. 4.3.1 Global Liraglutide Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Liraglutide Sales Value by Type (2021-2032)
  11. 4.3.3 Global Liraglutide Sales Value Share by Type (2021-2032)
5 Liraglutide Market by Application
  1. 5.1 Liraglutide Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drug Store
  4. 5.2 Global Liraglutide Sales Volume by Application
  5. 5.2.1 Global Liraglutide Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Liraglutide Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Liraglutide Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Liraglutide Sales Value by Application
  9. 5.3.1 Global Liraglutide Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Liraglutide Sales Value by Application (2021-2032)
  11. 5.3.3 Global Liraglutide Sales Value Share by Application (2021-2032)
6 Liraglutide Regional Sales and Value Analysis
  1. 6.1 Global Liraglutide Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liraglutide Sales by Region (2021-2032)
  3. 6.2.1 Global Liraglutide Sales by Region: 2021-2026
  4. 6.2.2 Global Liraglutide Sales by Region (2027-2032)
  5. 6.3 Global Liraglutide Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Liraglutide Sales Value by Region (2021-2032)
  7. 6.4.1 Global Liraglutide Sales Value by Region: 2021-2026
  8. 6.4.2 Global Liraglutide Sales Value by Region (2027-2032)
  9. 6.5 Global Liraglutide Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Liraglutide Sales Value (2021-2032)
  12. 6.6.2 North America Liraglutide Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Liraglutide Sales Value (2021-2032)
  15. 6.7.2 Europe Liraglutide Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Liraglutide Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Liraglutide Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Liraglutide Sales Value (2021-2032)
  21. 6.9.2 South America Liraglutide Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Liraglutide Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Liraglutide Sales Value Share by Country, 2025 VS 2032
7 Liraglutide Country-level Sales and Value Analysis
  1. 7.1 Global Liraglutide Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Liraglutide Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Liraglutide Sales by Country (2021-2032)
  4. 7.3.1 Global Liraglutide Sales by Country (2021-2026)
  5. 7.3.2 Global Liraglutide Sales by Country (2027-2032)
  6. 7.4 Global Liraglutide Sales Value by Country (2021-2032)
  7. 7.4.1 Global Liraglutide Sales Value by Country (2021-2026)
  8. 7.4.2 Global Liraglutide Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Liraglutide Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Liraglutide Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Liraglutide Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Liraglutide Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Liraglutide Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Liraglutide Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Liraglutide Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Liraglutide Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Liraglutide Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Liraglutide Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Liraglutide Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Liraglutide Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Liraglutide Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Liraglutide Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Liraglutide Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Liraglutide Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Liraglutide Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Liraglutide Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Liraglutide Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Liraglutide Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Liraglutide Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Liraglutide Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Liraglutide Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Liraglutide Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Liraglutide Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Liraglutide Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Liraglutide Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Liraglutide Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Liraglutide Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Liraglutide Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Liraglutide Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Liraglutide Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Liraglutide Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Liraglutide Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Liraglutide Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Liraglutide Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Liraglutide Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Liraglutide Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Liraglutide Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Liraglutide Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Liraglutide Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Liraglutide Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Liraglutide Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Liraglutide Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Liraglutide Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Liraglutide Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Liraglutide Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Liraglutide Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Liraglutide Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Liraglutide Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Liraglutide Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Liraglutide Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Liraglutide Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Liraglutide Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Liraglutide Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Liraglutide Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Liraglutide Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Liraglutide Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Liraglutide Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Liraglutide Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Liraglutide Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Liraglutide Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Liraglutide Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Liraglutide Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Liraglutide Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Liraglutide Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Liraglutide Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Liraglutide Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Liraglutide Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Liraglutide Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Liraglutide Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Liraglutide Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Liraglutide Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Liraglutide Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Liraglutide Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Liraglutide Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Liraglutide Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Liraglutide Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Liraglutide Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Liraglutide Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Liraglutide Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Liraglutide Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Liraglutide Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Liraglutide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 HEC Pharm
  2. 8.1.1 HEC Pharm Company Information
  3. 8.1.2 HEC Pharm Business Overview
  4. 8.1.3 HEC Pharm Liraglutide Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 HEC Pharm Liraglutide Product Portfolio
  6. 8.1.5 HEC Pharm Recent Developments
  7. 8.2 Bachem
  8. 8.2.1 Bachem Company Information
  9. 8.2.2 Bachem Business Overview
  10. 8.2.3 Bachem Liraglutide Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bachem Liraglutide Product Portfolio
  12. 8.2.5 Bachem Recent Developments
  13. 8.3 Bharat Pharmaceuticals
  14. 8.3.1 Bharat Pharmaceuticals Company Information
  15. 8.3.2 Bharat Pharmaceuticals Business Overview
  16. 8.3.3 Bharat Pharmaceuticals Liraglutide Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bharat Pharmaceuticals Liraglutide Product Portfolio
  18. 8.3.5 Bharat Pharmaceuticals Recent Developments
  19. 8.4 Kingpep Biotechnology
  20. 8.4.1 Kingpep Biotechnology Company Information
  21. 8.4.2 Kingpep Biotechnology Business Overview
  22. 8.4.3 Kingpep Biotechnology Liraglutide Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Kingpep Biotechnology Liraglutide Product Portfolio
  24. 8.4.5 Kingpep Biotechnology Recent Developments
  25. 8.5 Shenzhen JYMed Technology
  26. 8.5.1 Shenzhen JYMed Technology Company Information
  27. 8.5.2 Shenzhen JYMed Technology Business Overview
  28. 8.5.3 Shenzhen JYMed Technology Liraglutide Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Shenzhen JYMed Technology Liraglutide Product Portfolio
  30. 8.5.5 Shenzhen JYMed Technology Recent Developments
  31. 8.6 Wuxi Asiapeptide
  32. 8.6.1 Wuxi Asiapeptide Company Information
  33. 8.6.2 Wuxi Asiapeptide Business Overview
  34. 8.6.3 Wuxi Asiapeptide Liraglutide Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Wuxi Asiapeptide Liraglutide Product Portfolio
  36. 8.6.5 Wuxi Asiapeptide Recent Developments
  37. 8.7 AmbioPharm
  38. 8.7.1 AmbioPharm Company Information
  39. 8.7.2 AmbioPharm Business Overview
  40. 8.7.3 AmbioPharm Liraglutide Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AmbioPharm Liraglutide Product Portfolio
  42. 8.7.5 AmbioPharm Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Liraglutide Value Chain Analysis
  2. 9.1.1 Liraglutide Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Liraglutide Sales Mode & Process
  6. 9.2 Liraglutide Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Liraglutide Distributors
  9. 9.2.3 Liraglutide Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst